“The JAMA article and the resulting news reports reinforce, in my view, the value of the research we are doing with Oxycyte,” said company chairman and CEO Chris J. Stern, DBA.

“Oxycyte is a perfluorocarbon (PFC) therapeutic oxygen-carrying intravenous emulsion that can carry five times more oxygen than hemoglobin, making it an effective means of transporting oxygen to tissues and carbon dioxide to the lungs for disposal. Because it is a PFC and not based on hemoglobin, it does not have the safety issues identified in the JAMA article. In fact, there have been no adverse events in our clinical trials to date that were related to Oxycyte,” said Stern.

As announced previously, the company will ask shareholders to approve a name change in the proxy statement that was mailed this week pertaining to a shareholder meeting scheduled for June 17, 2008. The new name proposed for the company is Oxygen Biotherapeutics, Inc. Adopting a new name will better reflect the broader scope of the company’s development activities.

“We have several exciting bio-therapeutic solutions in the making, yet none of them is synthetic blood. As we saw with the news stories that resulted from the JAMA article, our current name causes us to be erroneously lumped in with some problematic products,” said Stern. “We will work to make sure that regulatory officials are aware of the differences between HBOCs and Oxycyte.”

About Synthetic Blood International

Synthetic Blood International is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and continuous substrate monitoring. The Company has under development an oxygen therapeutic/blood substitute and a liquid ventilation product, and an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs, and medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including acute respiratory distress syndrome, stroke, myocardial infarction, surgery, trauma, malignant tumors and diabetes. For further information, visit www.sybd.com.

Abe Wischnia & Associates
Abe Wischnia
619-795-2345